Announcements Trials
Browse Landscape

Phase

Phase 1 22Phase 2 10Phase 1/2 5Phase 3 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 147Thoracic 8Sarcoma 5Tumor-Agnostic 3Gynecologic 3CNS 3Other solid neoplasm 1Genitourinary 1Endocrine 1Breast 1

Conditions

Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Carcinoma 1Adenocarcinoma 1

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Irinotecan × Tumor-Agnostic × Clear all
NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed
512 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT00193596 2013-05-03

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 3 Completed
198 enrolled 7 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡